212 related articles for article (PubMed ID: 27810470)
1. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles.
Cavaco MC; Pereira C; Kreutzer B; Gouveia LF; Silva-Lima B; Brito AM; Videira M
Eur J Pharm Biopharm; 2017 Jan; 110():76-84. PubMed ID: 27810470
[TBL] [Abstract][Full Text] [Related]
2. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles.
Baek JS; Cho CW
Int J Pharm; 2015 Jan; 478(2):617-24. PubMed ID: 25510604
[TBL] [Abstract][Full Text] [Related]
3. Enhanced anticancer activity and intracellular uptake of paclitaxel-containing solid lipid nanoparticles in multidrug-resistant breast cancer cells.
Xu W; Bae EJ; Lee MK
Int J Nanomedicine; 2018; 13():7549-7563. PubMed ID: 30532538
[TBL] [Abstract][Full Text] [Related]
4. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z
J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
6. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.
Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
Drug Deliv; 2012 Nov; 19(8):363-70. PubMed ID: 23030458
[TBL] [Abstract][Full Text] [Related]
7. [Cytological Study in vitro on Co-delivery of siRNA and Paclitaxel within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors].
Huang R; Yao X; Chen Y; Sun X; Lin Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2016 Feb; 33(1):108-14. PubMed ID: 27382749
[TBL] [Abstract][Full Text] [Related]
8. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Baek JS; Cho CW
J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
Jin X; Mo R; Ding Y; Zheng W; Zhang C
Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Wang F; Li L; Liu B; Chen Z; Li C
Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors.
Yoshizawa Y; Ogawara K; Kimura T; Higaki K
Eur J Pharm Sci; 2014 Oct; 62():274-80. PubMed ID: 24956463
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment.
Katiyar SS; Muntimadugu E; Rafeeqi TA; Domb AJ; Khan W
Drug Deliv; 2016 Sep; 23(7):2608-2616. PubMed ID: 26036652
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
Wang F; Zhang D; Zhang Q; Chen Y; Zheng D; Hao L; Duan C; Jia L; Liu G; Liu Y
Biomaterials; 2011 Dec; 32(35):9444-56. PubMed ID: 21903258
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
15. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
[TBL] [Abstract][Full Text] [Related]
16. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
Nobili S; Landini I; Mazzei T; Mini E
Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
[TBL] [Abstract][Full Text] [Related]
17. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Patil Y; Sadhukha T; Ma L; Panyam J
J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer.
Ren F; Chen R; Wang Y; Sun Y; Jiang Y; Li G
Pharm Res; 2011 Apr; 28(4):897-906. PubMed ID: 21184150
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
